A Phase Ib Randomized, Placebo-controlled, Double-blinded Study Evaluating the Safety of Ataciguat (HMR1766) in Patients With Moderate Calcific Aortic Valve Stenosis

Trial Profile

A Phase Ib Randomized, Placebo-controlled, Double-blinded Study Evaluating the Safety of Ataciguat (HMR1766) in Patients With Moderate Calcific Aortic Valve Stenosis

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2016

At a glance

  • Drugs Ataciguat (Primary)
  • Indications Aortic valve stenosis
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jul 2016 Status changed from recruiting to completed.
    • 09 Feb 2015 Planned End Date changed from 1 Jan 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
    • 09 Apr 2014 New source integrated (Mayo Clinic; 13-005387)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top